Serum Brain-Derived Neurotrophic Factor Level, Plasma 3-Methoxy-4-Hydroxyphenylglycol Level in Major Depressed Patients with Paroxetine Monotherapy

Abstract

Statistical AnalysisRelations between the clinical response, serum biomarkers, and paroxerine levels were analyzed using Spearman correlation. In addition, findings were corrected for multiple comparisons via Bonferroni correction. Significance of results was set at p<0.05. Result Changes of the HAMD17 scores and plasma MHPG levelsNo association was found between the HAMD17 scores and plasma MHPG levels (rho=-0.0774, p=0.8413) (Figure 1). AbstractObjective: We investigated the relationships among clinical efficacy, brain-derived neurotrophic factor (BDNF), 3-methoxy-4-hydroxyphenylglycol (MHPG), and paroxetine concentration in patients with major depressive disorder (MDD) who treated with paroxetine monotherapy.

Can Plasma Level of 3-methoxy-4-hydroxyphenylglycol Predict the Response for Selective Serotonin Reuptake Inhibitor and Serotonin Noradrenaline Reuptake Inhibitor in Major Depressive Disorder?

“…We also found that plasma MHPG is useful for predicting relapse to a major depressive episode in MDD patients [8]. Another of our studies showed that switching from paroxetine to milnacipran did not alter plasma MHPG levels [9]. We conducted the present study to investigate whether MDD patients' responses to an SSRI and an SNRI can be predicted based on plasma MHPG.…”

“…When administered to patients with MDD, some antidepressants increase plasma MHPG, whereas other antidepressants decrease or do not change the plasma MHPG level. We demonstrated that paroxetine, an SSRI, decreased plasma MHPG, and that the SNRI milnacipran increased plasma MHPG; we also reviewed the effects of several antidepressants on plasma MHPG levels [3][4][5][6][7][8][9]. We also found that plasma MHPG is useful for predicting relapse to a major depressive episode in MDD patients [8].…”

Insights on the Anxiety Disorders

“…The study of Yoshimura et al has meticulously studied the relationships among clinical efficacy, brain-derived neurotrophic factor (BDNF), 3-methoxy-4-hydroxyphenylglycol (MHPG), and paroxetine concentration in patients with major depressive disorder (MDD) treated with paroxetine monotherapy [5]. Aragão-Almeida et al study evaluated the possible influence of the ovarian cycle of healthy women on the acute effect of diazepam.…”